January 4, 2018 / 10:55 PM / 6 months ago

BRIEF-Helix Biopharma Signs Binding Letter Of Intent For Development Of New Car-T Technologies

Jan 4 (Reuters) - Helix Biopharma Corp:

* HELIX BIOPHARMA CORP. SIGNS BINDING LETTER OF INTENT FOR DEVELOPMENT OF NEW CAR-T TECHNOLOGIES

* SAYS‍ IMMEDIATE FOCUS WILL INVOLVE PRECLINICAL WORK IN SUPPORT OF A NEW IND APPLICATION OF A CAR-T FOR HEMATOLOGICAL MALIGNANCIES​

* SAYS ‍FINALIZATION OF COLLABORATIVE BINDING LOI WITH PROMAB BIOTECHNOLOGIES TO DEVELOP CHIMERIC ANTIGEN RECEPTOR CAR-T FOR HEMATOLOGICAL MALIGNANCES AND SOLID TUMOURS​

* SAYS UNDER AGREEMENT,CO RETAINS EXCLUSIVE LICENSE FOR COMMERCIALIZATION OF PRODUCT CANDIDATES DEVELOPED ALONE OR IN COMBINATION WITH DOS47​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below